Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

IκBα controls dormancy in hematopoietic stem cells via retinoic acid during embryonic development

  • Thambyrajah, Roshana
  • Maqueda, Maria
  • Fadlullah, Zaki
  • Proffitt, Martin
  • Neo, Wen Hao
  • Guillén, Yolanda
  • Casado-Peláez, Marta
  • Herrero-Molinero, Patricia
  • Brujas, Carla
  • Castelluccio, Noemi
  • González, Jessica
  • Iglesias, Arnau
  • Marruecos, Laura
  • Ruiz-Herguido, Cristina
  • Esteller, Manel
  • Mereu, Elisabetta
  • Lacaud, Georges
  • Espinosa Blay, Lluís
  • Bigas Salvans, Anna
Recent findings suggest that Hematopoietic Stem Cells (HSC) and progenitors arise simultaneously and independently of each other already in the embryonic aorta-gonad mesonephros region, but it is still unknown how their different features are established. Here, we uncover IκBα (Nfkbia, the inhibitor of NF-κB) as a critical regulator of HSC proliferation throughout development. IκBα balances retinoic acid signaling levels together with the epigenetic silencer, PRC2, specifically in HSCs. Loss of IκBα decreases proliferation of HSC and induces a dormancy related gene expression signature instead. Also, IκBα deficient HSCs respond with superior activation to in vitro culture and in serial transplantation. At the molecular level, chromatin regions harboring binding motifs for retinoic acid signaling are hypo-methylated for the PRC2 dependent H3K27me3 mark in IκBα deficient HSCs. Overall, we show that the proliferation index in the developing HSCs is regulated by a IκBα-PRC2 axis, which controls retinoic acid signaling., This work was funded by grants from SAF2016-75613-R, PID2019-104695RB-I00, and PDC2021-120817-I00 from Agencia Estatal de Investigación (AEI) and SLT002/16/00299 from Department of Health, Generalitat de Catalunya. The work in G.L. laboratory is supported by Blood Cancer UK (19014) and Cancer Research UK Manchester Institute Core Grant (C5759/A27412). R.T. is a recipient of BP2016(00021) and BP/MSCA 2018(00034) fellowship programs from Generalitat de Catalunya/MSCA. M.M. is a recipient of a grant from the Instituto Carlos III, grant number CA22/00011 (co-funded by the European Social Fund Plus, ESF+, and by the European Union).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Using pluripotent stem cells to understand normal and leukemic hematopoietic development

  • Bigas Salvans, Anna
  • Galán i Palma, Luis
  • Kartha, Gayathri M.
  • Giorgetti, Alessandra
Several decades have passed since the generation of the first embryonic stem cell (ESC) lines both in mice and in humans. Since then, stem cell biologists have tried to understand their potential biological and clinical uses for their implementation in regenerative medicine. The hematopoietic field was a pioneer in establishing the potential use for the development of blood cell products and clinical applications; however, early expectations have been truncated by the difficulty in generating bonafide hematopoietic stem cells (HSCs). Despite some progress in understanding the origin of HSCs during embryonic development, the reproduction of this process in vitro is still not possible, but the knowledge acquired in the embryo is slowly being implemented for mouse and human pluripotent stem cells (PSCs). In contrast, ESC-derived hematopoietic cells may recapitulate some leukemic transformation processes when exposed to oncogenic drivers. This would be especially useful to model prenatal leukemia development or other leukemia-predisposing syndromes, which are difficult to study. In this review, we will review the state of the art of the use of PSCs as a model for hematopoietic and leukemia development., This work was funded by grants from PID2019-104695RB-I00 and PDC2021-120817-I00from AgenciaEstatal de Investigación (AEI) to AB, ERA PerMed GATA2-HuMo Funding Mechanism (Spain: Acció instrumental de SLT011/18/00006 and SLT011/18/00007 of the Department of Health of the Government of Catalonia to AG and A, the Spanish Ministry of Economy, Industry, and Competitiveness (MINECO PID2020-15591RB-100), La Marató de TV3 (202001-32) and CERCA Programme/Generalitat de Catalunya for institutional support to AG. LGP is a recipient of 2021 FI_B2 00188, AGAUR, Generalitat de Cataluña.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

IκBα controls dormancy in hematopoietic stem cells via retinoic acid during embryonic development

  • Thambyrajah, Roshana
  • Maqueda, Maria
  • Fadlullah, Zaki
  • Proffitt, Martin
  • Neo, Wen Hao
  • Guillén, Yolanda
  • Casado-Peláez, Marta
  • Herrero-Molinero, Patricia
  • Brujas, Carla
  • Castelluccio, Noemi
  • González, Jessica
  • Iglesias, Arnau
  • Marruecos, Laura
  • Ruiz-Herguido, Cristina
  • Esteller, Manel
  • Mereu, Elisabetta
  • Lacaud, Georges
  • Espinosa Blay, Lluís
  • Bigas Salvans, Anna
Recent findings suggest that Hematopoietic Stem Cells (HSC) and progenitors arise simultaneously and independently of each other already in the embryonic aorta-gonad mesonephros region, but it is still unknown how their different features are established. Here, we uncover IκBα (Nfkbia, the inhibitor of NF-κB) as a critical regulator of HSC proliferation throughout development. IκBα balances retinoic acid signaling levels together with the epigenetic silencer, PRC2, specifically in HSCs. Loss of IκBα decreases proliferation of HSC and induces a dormancy related gene expression signature instead. Also, IκBα deficient HSCs respond with superior activation to in vitro culture and in serial transplantation. At the molecular level, chromatin regions harboring binding motifs for retinoic acid signaling are hypo-methylated for the PRC2 dependent H3K27me3 mark in IκBα deficient HSCs. Overall, we show that the proliferation index in the developing HSCs is regulated by a IκBα-PRC2 axis, which controls retinoic acid signaling., This work was funded by grants from SAF2016-75613-R, PID2019-104695RB-I00, and PDC2021-120817-I00 from Agencia Estatal de Investigación (AEI) and SLT002/16/00299 from Department of Health, Generalitat de Catalunya. The work in G.L. laboratory is supported by Blood Cancer UK (19014) and Cancer Research UK Manchester Institute Core Grant (C5759/A27412). R.T. is a recipient of BP2016(00021) and BP/MSCA 2018(00034) fellowship programs from Generalitat de Catalunya/MSCA. M.M. is a recipient of a grant from the Instituto Carlos III, grant number CA22/00011 (co-funded by the European Social Fund Plus, ESF+, and by the European Union).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Using pluripotent stem cells to understand normal and leukemic hematopoietic development

  • Bigas Salvans, Anna
  • Galán i Palma, Luis
  • Kartha, Gayathri M.
  • Giorgetti, Alessandra
Several decades have passed since the generation of the first embryonic stem cell (ESC) lines both in mice and in humans. Since then, stem cell biologists have tried to understand their potential biological and clinical uses for their implementation in regenerative medicine. The hematopoietic field was a pioneer in establishing the potential use for the development of blood cell products and clinical applications; however, early expectations have been truncated by the difficulty in generating bonafide hematopoietic stem cells (HSCs). Despite some progress in understanding the origin of HSCs during embryonic development, the reproduction of this process in vitro is still not possible, but the knowledge acquired in the embryo is slowly being implemented for mouse and human pluripotent stem cells (PSCs). In contrast, ESC-derived hematopoietic cells may recapitulate some leukemic transformation processes when exposed to oncogenic drivers. This would be especially useful to model prenatal leukemia development or other leukemia-predisposing syndromes, which are difficult to study. In this review, we will review the state of the art of the use of PSCs as a model for hematopoietic and leukemia development., This work was funded by grants from PID2019-104695RB-I00 and PDC2021-120817-I00from AgenciaEstatal de Investigación (AEI) to AB, ERA PerMed GATA2-HuMo Funding Mechanism (Spain: Acció instrumental de SLT011/18/00006 and SLT011/18/00007 of the Department of Health of the Government of Catalonia to AG and A, the Spanish Ministry of Economy, Industry, and Competitiveness (MINECO PID2020-15591RB-100), La Marató de TV3 (202001-32) and CERCA Programme/Generalitat de Catalunya for institutional support to AG. LGP is a recipient of 2021 FI_B2 00188, AGAUR, Generalitat de Cataluña.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

IκBα controls dormancy in hematopoietic stem cells via retinoic acid during embryonic development

  • Thambyrajah, Roshana|||0000-0002-3941-760X
  • Maqueda, Maria|||0000-0001-9304-1714
  • Fadlullah, Muhammad Zaki|||0000-0002-3111-8090
  • Proffitt, Martin
  • Neo, Wen Hao|||0000-0002-6827-3027
  • Guillén, Yolanda|||0000-0001-8673-6470
  • Casado Pelaez, Marta|||0000-0002-8428-8384
  • Herrero-Molinero, Patricia
  • Brujas, Carla
  • Castelluccio, Noemi|||0000-0003-2635-4889
  • González Miranda, Jessica|||0000-0001-7732-1564
  • Iglesias, Arnau|||0000-0002-7195-7868
  • Marruecos, Laura|||0000-0002-4206-709X
  • Ruiz-Herguido, Cristina
  • Esteller, M|||0000-0003-4490-6093
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Lacaud, Georges|||0000-0002-5630-2417
  • Espinosa, Lluis|||0000-0002-2897-4099
  • Bigas Salvans, Anna|||0000-0003-4801-6899
Recent findings suggest that Hematopoietic Stem Cells (HSC) and progenitors arise simultaneously and independently of each other already in the embryonic aorta-gonad mesonephros region, but it is still unknown how their different features are established. Here, we uncover IκBα (Nfkbia, the inhibitor of NF-κB) as a critical regulator of HSC proliferation throughout development. IκBα balances retinoic acid signaling levels together with the epigenetic silencer, PRC2, specifically in HSCs. Loss of IκBα decreases proliferation of HSC and induces a dormancy related gene expression signature instead. Also, IκBα deficient HSCs respond with superior activation to in vitro culture and in serial transplantation. At the molecular level, chromatin regions harboring binding motifs for retinoic acid signaling are hypo-methylated for the PRC2 dependent H3K27me3 mark in IκBα deficient HSCs. Overall, we show that the proliferation index in the developing HSCs is regulated by a IκBα-PRC2 axis, which controls retinoic acid signaling.